Evicenter
P&T meetings

Anaphylm (dibutepinephrine)

Type I allergic reactions including anaphylaxis

Also known as AQST-109
Regulatory submission
NDA resubmitted September 2026
Launch
Not announced
Last updated
121 sources

Product information and disease descriptionProduct descriptionProduct information

Co-prescribed/Concomitant therapies

2 evidence topics · 2 sources

Additional epinephrine doses in anaphylaxis management

“Treatment of anaphylaxis typically consists of an intramuscular injection of epinephrine administered at the earliest opportunity, followed by additional intramuscular or intravenous injections as needed.” (opens the source at this quote in a new tab)

“People with known allergies and who are at risk for anaphylaxis are advised to carry two epinephrine auto-injectors with them at all times and self-administer at the first signs of an anaphylactic reaction.” (opens the source at this quote in a new tab)

Repeat-dose exposure in the clinical development program

“including 840 single-dose and 127 repeat-dose exposures of Anaphylm” (opens the source at this quote in a new tab)

Concomitant antihistamines or corticosteroids

No evidence found.